Driving Innovation

HAV logo

News

MAY 2018

Share subscriptions closed at £2.7 million
HVL raised £2.7 million in its two rounds of financing. The second round closed at the end of 2017.

Phase 1 trial
The Phase 1 trial of HVL’s priming vector, ChAdOx2 HAV has been completed. The vaccine proved to be safe and well tolerated and no severe or serious adverse events were recorded.

A follow-on prime/boost Phase 1 trial will commence shortly.

Phase 2 trial
The design of a Phase 2 trial of HVL’s priming vector is being finalised.

March 2017

Share subscriptions reach £2.5 million
HVL has now raised £2.5 million in its two rounds of financing.

Phase 1 trial
The Phase 1 trial of HVL's priming vector ChAdOx2 HAV has begun at the Jenner Institute Oxford University.

JULY 2016

Share subscriptions reach £1.9 million
Having closed off its first round funding at £1.5 million, HVL has so far raised a further £0.4 million in its second round financing.

GMP manufacture
GMP manufacture of over 300 vials of HVL’s priming vector ChAdOx2 HAV has been completed and these are now ready for use in our Phase 1 trials.
GMP manufacture of HVL’s boost vector MVA HAV is expected to be completed at the end of September.

JANUARY 2016

Share subscriptions reach £1.5 million
HVL has now raised a total of £1.5 million of subscription monies for new shares in HVL and has issued the relevant shares.

GMP manufacture
GMP manufacture of HVL’s priming vector ChAdOx2 HAV began in November 2015 at the Clinical BioManufacturing Facility at Oxford University.

GMP manufacture of HVL’s boost vector MVA HAV began in January 2016 at IDT Biologika GmbH in Germany. .

Board change
Following his move to New Zealand Allan Cambridge has resigned as a director of HVL. At the Board’s invitation he has taken up the position of Commercial Officer

AUGUST 2015

Share subscriptions reach £1.2 million
In recent months HVL has continued to attract investment interest and has now received £1.2 million of subscription monies for new shares in HVL and has informal commitments for a further £100,000.

GMP Manufacture
On 4th August, HVL entered into an agreement with The Clinical BioManufacturing Facility at Oxford University for the GMP manufacture of our vaccine’s key priming vector ChAdOx2 HAV. This follows on from the pre-GMP work which is now in its final stages and reinforces the close collaboration between HVL and the Jenner Institute at Oxford University in the development of HVL’s anti-MAP vaccine for the treatment of Crohn’s Disease.

MAY 2015

Share subscriptions reach £1 million
HVL has raised a further £350,000 (and issued the relevant shares) and is now looking to raise the next tranche to complete the necessary funding for the manufacture of the vaccine’s Boost Dose component (MVA.HAV) and the Phase 1 trials of ChAdOx2.HAV and MVA.HAV.

Pre-GMP Manufacture
Work is progressing at the Jenner Institute at Oxford University in relation to the pre-GMP development work of the key Prime Dose component of the vaccine (ChAdOx2.HAV) and will commence shortly on the Boost Dose component (MVA.HAV).

GMP manufacture of both components is expected to commence in the last quarter of 2015. 

FEBRUARY 2015

GMP Manufacture
HVL has concluded an agreement with the Jenner Institute at Oxford University for the pre-GMP development work required in advance of manufacture. Jenner has already begun this preparatory work and it is expected that full GMP manufacture will begin in May.

Share subscriptions
HVL has been granted advanced EIS approval.

HVL has raised £650,000 (and issued the relevant shares) and has informal commitments for a further £100,000. The funds raised are anticipated to cover the cost of manufacture of the vaccine’s key priming vector (ChAdOx2.HAV). HVL is now looking to raise the next tranche of funding for the Phase 1 trial of ChAdOx2.HAV and the manufacture of the vaccine’s boost vector (MVA.HAV).

30 OCTOBER 2014

Dr Amy Hermon-Taylor, a London GP and daughter of Prof Hermon-Taylor, has joined forces with a team of Crohn’s sufferers and their families to increase awareness of MAP as a major causative agent of CD and to secure donations to fund the final stages of development of the MAP diagnostic at Kings College London.

Their group launched its new website www.crohnsmapvaccine.com on 23rd June 2014. Interest in the website and engagement with their Facebook page https://www.facebook.com/crohnsmapvaccine (with over 6500 followers) is indicative of the depth of support for this project amongst the Crohn’s community. To date, £40,000 has been donated to Kings College for the development of the diagnostic agent.

30 OCTOBER 2014

HVL’s clinical development partner, The Jenner Institute at Oxford University, was awarded a £2.8million grant from the Wellcome Trust, the Department for International Development and the Medical Research Council to start clinical trials of an Ebola vaccine in the UK. The NIH/GSK Ebola vaccine works in the same way as the HAV anti-MAP vaccine by using non-replicating genetic material derived from the infecting organism inserted into a non-replicating harmless strain of chimpanzee cold virus (ChAd).